Grail (NASDAQ: GRAL)
$48.43
(-1.9%)
-$0.95
Price as of June 27, 2025, 3:58 p.m. ET
Grail Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Grail Company Info
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.